

Visual Functional Defects in Patients with type 2 Diabetes Mellitus: A Questionnaire Based Cross-Sectional Study

Yimeng Ge (✉ gym_susan@pku.edu.cn)

Peking University Third Hospital <https://orcid.org/0000-0001-8939-8681>

Sanbao Chai

Peking University International Hospital

Yu Wan

Peking University Third Hospital

Huaqin Xia

Peking University Third Hospital

Ruilan Dong

Peking University Third Hospital

Qingyi Hou

Peking University Third Hospital

Xiaotong Ren

Peking University Third Hospital

Hao Yuan

Peking University Third Hospital

Jiarui Yang

Peking University Third Hospital

Xuemin Li

Peking University Third Hospital

Research Article

Keywords: Type 2 diabetes, visual functions, retinopathy, quality of life

Posted Date: September 30th, 2021

DOI: <https://doi.org/10.21203/rs.3.rs-925224/v1>

License:   This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

1 **Visual functional defects in patients with type 2 diabetes mellitus: a questionnaire based**

2 **cross-sectional study**

3 **Sanbao Chai^{1,†}, Yimeng Ge^{2,†}, Yu Wan², Huaqin Xia², Ruilan Dong², Xiaotong Ren², Hao Yuan²,**

4 **Qingyi Hou², Jiarui Yang^{2,*} and Xuemin Li^{2,*}**

5 ¹Department of Endocrinology and Metabolism, Peking University International Hospital, Beijing,

6 102206, P R China

7 ²Department of Ophthalmology, Peking University Third Hospital, Beijing key laboratory of restoration

8 of damaged ocular nerve, Peking University Third Hospital, 49 North Garden Road, Haidian District,

9 Beijing 100191, P R China

10 [†]These authors contributed equally to this work

11 *Corresponding Author A: lxm66@sina.com

12 *Corresponding author B: Jiarui Yang; jiaruiyang@bjmu.edu.cn

13 **Author Contributions**

14 Study design and concept: Sanbao Chai, Jiarui Yang, Xuemin Li; Data collection and analysis: Yimeng

15 Ge, Yu Wan; Interpretation of data and critical revision of the manuscript: Sanbao Chai, Yimeng Ge,

16 Huaqin Xia, Ruilan Dong, Xiaotong Ren, Hao Yuan, Qingyi Hou, Jiarui Yang; All authors have read

17 and approved the final draft of the manuscript submitted.

18 **Funding**

19 This study was supported by Beijing Key Laboratory Opening Funding(Grant number:

20 BKLOF-BYSY202101)

21 **Compliance of ethical standards**

22 **Conflict of interest**

23 The authors declared that they have no conflict of interest

24 **Ethical approval**

25 All procedures performed in studies involving human participants were in accordance with the ethical
26 standards of the institutional and national research committee (Peking University Third Hospital
27 Medical Science Research Ethics Committee, S2020023) and with the 1964 Helsinki Declaration and
28 its later amendments or comparable ethical standards.

29 **Informed Consent**

30 Informed consent was obtained from all individual participants included in the study.

31 **Abstract**

32 *Purpose*

33 To determine the impact of type 2 diabetes mellitus (T2DM) on visual functions, identify different
34 modifiers as risk or protective factors, and find out how these factors affect patients' visual symptoms
35 and vision-related quality of life as a whole.

36 *Methods*

37 We performed an online survey among 1242 participants (400 patients, 842 non-patients).

38 Demographic features and severity of disease were documented, while visual functions were evaluated
39 using National Eye Institute Visual Functioning questionnaire-25 (NEI VFQ-25). Independent t-test,
40 analysis of variance, linear and non-linear regression models were used to assess all data.

41 ***Results***

42 Scores other than color vision among T2DM patients were significantly lower compared with
43 non-T2DM participants. There was significant difference after stratification of age and education, but
44 no significant difference between different genders was observed. Parameters including duration of
45 T2DM, fasting plasma glucose (FPG) and glycosylated hemoglobin A1c (HbA1c) negatively impacted
46 on the scores, with 20 years' of diabetic duration, 10mmol/L of FPG, 7.5% of HbA1c being potential
47 cut-off points. Poorer best corrected visual acuity (BCVA) and diagnosis of diabetic retinopathy were
48 risk factors, while they simultaneously produced mediation effect, contributing 5%-78% of effect in the
49 deterioration of visual functions caused by longer diabetic duration and higher blood glucose.

50 ***Conclusion***

51 Significant visual impairments and faster deterioration in visual functions were seen in T2DM patients,
52 with older age, lower educational level, longer diabetic duration, poorer blood glucose administration,
53 limited BCVA, and the presence of diabetic retinopathy identified as risk factors. Average BCVA and
54 diabetic retinopathy also yielded mediation effect as diabetic duration lengthened and blood glucose
55 elevated.

56 **Keywords**

57 Type 2 diabetes, visual functions, retinopathy, quality of life

58 **Introduction**

59 Type 2 Diabetes Mellitus (T2DM) is one of the most common yet severe metabolic diseases affecting
60 millions of people worldwide^[1]. With global, regional and country-level estimates, it is predicted that
61 the prevalence, mortality rate and health expenditure are all likely to go through a dramatic increase in
62 both developed and developing countries^[2]. Additionally, T2DM is associated with multiple
63 ophthalmologic complications, specifically diabetic retinopathy^[3] and diabetic macular edema^[4], which
64 are thought to severely impact on patients' vision and thus led to decreased vision-related quality of life
65 and other adverse clinical outcomes. Other minor visual problems related to alterations in refractive
66 error, contrast sensitivity, straylight and presbyopia also contributed to visual impairments and
67 disturbance in T2DM patients. As estimated by the WHO Multinational Study of Vascular Disease in
68 Diabetes (WMSVDD) in a 8.4-year follow-up covering 10 centers across the globe, the cumulative
69 incidence of mild, moderate and severe visual impairments in T2DM patients were 9.43%, 3.21% and
70 2.25% respectively^[5]. Therefore, the evaluation of visual function should serve as an importance
71 component to assess the well-being of T2DM patients and be treated as valuable trackers or predictors
72 that promote the overall administration of T2DM.

73 In prior studies, multiple rating scales featuring visual functional has already been administered to

74 T2DM patients with a few modifiers (e.g. old age, male gender) identified as risk factors. However, a
75 comprehensive analysis of different influence factors of visual functions and how these factors
76 collaboratively contribute to the progression of T2DM is still lacking. Our study aims to characterize
77 the pattern of visual impairment among T2DM patients in comparison with individuals free of T2DM,
78 identify certain demographic and disease-related features as protective or risk factors and analyze how
79 they interfere with each other and promote the overall development and prognosis of T2DM.

80 **Materials and methods**

81 ***2.1 Study Design***

82 With approval from the Ethics Committee of Peking University Third Hospital, a questionnaire was
83 sent out to patients and volunteers via the internet. The questionnaire was divided into three parts, with
84 the first part collecting basic information (age, gender, educational level), the second part featuring
85 severity of disease (diabetic duration, fasting glucose, glycosylated hemoglobin A1c, best corrected
86 visual acuity and the presence of diabetic retinopathy), and the last part determined visual performance
87 of patients using NEI VFQ-25, which was considered as a valid tool demonstrating multiple levels of
88 functional defects and inconvenience in conducting daily tasks among patients with chronic
89 ophthalmologic diseases^[3,6].

90 ***2.2 Study participants***

91 In this study, questionnaires were distributed through the Internet between June 12, 2020 and August 30,

92 2020. A total of 1244 individuals were screened, 400 were T2DM, and 844 were non-T2DM, which
93 yielded a representative sample for the respective communities. Further stratification was done based
94 on patients' age and duration of T2DM. 9 groups were formed in all participants with each group
95 possessed an age range of 10 years, while duration of T2DM were classified as 0-5 years, 5-10 years,
96 10-20 years, 20-30 years, and >30 years.

97 ***2.3 Information Collection***

98 The data of basic information, diabetic-related information, vision quality and vision-related quality of
99 life were collected. The duration of T2DM were considered as the time between initial diagnosis and
100 the time when NEI VFQ-25 was administered to the patient, while fasting plasma glucose (FPG) and
101 glycosylated hemoglobin A1c (HbA1c) were collected based on patients' self-reported data of recent
102 clinical examinations. Best corrected visual acuity (BCVA) of both eyes were specified as the result
103 from patients' last clinical visit. Decimal visual acuity, which is currently widely applied in clinical
104 practice in China, was collected, while the data was transformed to LogMAR for analysis. Meanwhile,
105 the presence of diabetic retinopathy was confirmed as patients having previous diagnosis in proper
106 healthcare settings.

107 The scores of NEI VFQ-25 of all participants were calculated according to the following procedures.
108 Patients were required to rate their performance in vision-related tasks with a 5 or 6 point scale ranging
109 from "having no difficulties at all" to "not being able to do this because of eyesight". A score of 0-100
110 were then given to each answer as 100 being the optimum and 0 being the worst. An answer of "stop

111 doing this for other reasons or not interested in doing this” was considered to be missing data. The
112 scores of 6 sub-scales were calculated as the average of scores for each question under this sub-scale,
113 while a total score was obtained through averaging of all sub-scale scores^[7].

114 **2.3 Statistical Analysis**

115 Statistical analysis was performed by using SPSS version 26.0 and R 4.0.4. The continuous variable
116 and categorical variables were presented as mean±standard deviation (SD) and frequency (%),
117 respectively. Independent t-test and analysis of variance were used to assess the data between T2DM
118 and control group while a *P*-value<0.05 was considered to be significant. Moreover, we applied a
119 non-linear regression model to describe the changes of vision-related in all sub-scales among two
120 groups with age. We also reported the changing of NEI VFQ-25 scores induced by aging, lengthening
121 of diabetic duration, elevation of FPG and HbA1c as well as deterioration of eyesight with restricted
122 cubic spline (smooth curve). Further mediation effect of average vision and baseline diabetic
123 retinopathy were assessed using mediation effect analysis.

124 **Results**

125 **3.1 Basic data**

126 The baseline characteristics of the participants were shown in Table 1. T2DM patients shared a mean
127 age of 59.01±11.38 years, 11.02±8.02 years of diabetic duration, 8.16±4.00 mmol/L of FPG and
128 8.23±5.85% of HbA1c respectively, while a mean age of 41.64±12.76 was shared by participants

129 without T2DM. 23.7% patients with T2DM were already diagnosed with retinopathy, whereas the
 130 average BCVA was 0.22 ± 0.31 and 0.19 ± 0.28 for the left and the right eye respectively.

131 **TABLE 1 Baseline characteristics of T2DM patients and Non-T2DM participants**

| Characteristics | T2DM (n=400) | Non-T2DM (n=844) | <i>p</i> -value |
|--------------------------|-----------------|---------------------|-----------------|
| Age, years | 59.01±11.38 | 41.64±12.76 | <0.001*** |
| Gender | | | |
| Male | 188 | 318 | <0.001*** |
| Female | 212 | 526 | |
| Educational level | | | |
| Illiteracy | 10 | 3 | <0.001*** |
| Primary School | 30 | 6 | |
| Secondary School | 89 | 40 | |
| High School | 102 | 132 | |
| Undergraduate | 157 | 576 | |
| Graduate or above | 12 | 87 | |
| Diabetic duration, years | 11.02±8.02 | | |
| FPG, mmol/L | 8.16±4.00 | | |
| HbA1c, % | 8.23±5.85 | | |
| BCVA | | | |
| Left | 0.22±0.31 | 0.15±0.18 | <0.001*** |
| Right | 0.19±0.28 | 0.09±0.11 | <0.001*** |

Diabetic Retinopathy

| | |
|-----|-----|
| Yes | 71 |
| No | 229 |

132 n=number, T2DM=Type 2 diabete mellitus, FPG=fasting plasma glucose, BCVA=best corrected visual

133 acuity, HbA1c= glycosylated hemoglobin A1c

134 $p < 0.001$ was marked with ***.

135 ***3.2 Functional defects in T2DM patients and Non-T2DM participants***

136 Both groups completed the questionnaire and visual functional defects in all participants were
137 relatively slight since mean scores for most sub-scales exceeded 90, demonstrating satisfactory
138 performance in all participants. Notably, the scores for “General Vision”, which was based on the
139 personal assessment of vision-related quality of life, were comparably lower in both groups, indicating
140 the need of alleviating visual symptoms or bettering visual performance even in participants not
141 suffering from T2DM.

142 As shown in Table 2, the total and mean scores for 5 NEI VFQ-25 sub-scales scores were lower in
143 T2DM group ($p < 0.001$, independent t-test). However, there was no significant difference between the
144 two groups in the scores of color vision. Furthermore, after stratification by age, gender and
145 educational level, we found that the performance of elderly patients with T2DM were worse than those
146 non-T2DM participants of the same age, in terms of distance activities ($p = 0.033$), social functioning
147 ($p = 0.006$), peripheral vision ($p = 0.025$) and total score ($p = 0.013$) (Supplementary Table 1). Similar


148 stratification was done with regard to gender and educational level. These results indicated that all
 149 sub-scales and total score in T2DM patients were lower than non-T2DM participants except for color
 150 vision after stratification by gender (Supplementary Table 2), while significant results were only seen
 151 in participants sharing an educational level of secondary school, high school and undergraduate
 152 (Supplementary Table 3). The scores of near activities ($p=0.007$) and distance activities ($p=0.021$) of
 153 T2DM with secondary school education background were lower than non-T2DM counterparts.
 154 Undergraduate T2DM patients, however, reported greater functional defects in near activities and social
 155 functioning with statistical significance ($p<0.001$, $p=0.012$) compared with non-T2DM participants.

156 **TABLE 2 Visual functional defects among T2DM patients and non-T2DM participants**

| Parameters | T2DM (n=400) | Non-T2DM (n=842) | <i>p</i> -value |
|---------------------|-----------------|---------------------|-----------------|
| Near activities | 82.46±21.90 | 92.63±12.09 | <0.001*** |
| Distance activities | 87.69±19.25 | 92.22±11.60 | <0.001*** |
| Social functioning | 93.25±15.17 | 97.17±8.19 | <0.001*** |
| General vision | 64.35±15.38 | 68.15±15.77 | <0.001*** |
| Peripheral vision | 90.87±19.38 | 94.93±12.19 | <0.001*** |
| Color vision | 94.68±15.28 | 93.98±13.47 | 0.423 |
| NEI VFQ-25 Total | 89.55±16.11 | 94.18±8.61 | <0.001*** |

157 n=number, T2DM=Type 2 diabete mellitus, NEI VFQ-25=National Eye Institute Visual Functioning
 158 questionnaire-25
 159 $p<0.001$ was marked with ***.

160 Furthermore, we applied a non-linear regression model to analyze the changes of vision-related
 161 subscales with age. As shown in Figure 1, near activities in both T2DM and non-T2DM participants
 162 presented constant decrease with age, whereas in other sub-scales, two groups were expected to reach
 163 their highest functional level at around age 40-50. Moreover, in sub-scales with such single peak
 164 shaped pattern, peak performance for T2DM patients seemed to be relatively lower than non-T2DM
 165 participants, while the scope of functional loss was higher after age 60. In the general vision sub-scale,
 166 non-T2DM participants tended to demonstrate a different pattern compared with T2DM patients as
 167 there was no direct negative correlation between the average score and age. Color vision, however,
 168 didn't exhibit a clear pattern of functional loss, as the mean score for this sub-scale didn't differ much
 169 as T2DM patients got older. These results indicated that apart from the lower scores in each sub-scale,
 170 T2DM patients simultaneously experienced faster worsening of various visual functions as they
 171 senesced.



172 **FIGURE 1 Correlation between visual functions and aging in T2DM patients (a) and non-T2DM**
 173 **participants (b).** We used restricted cubic spline to characterize the non-linear correlation between
 174 aging and scores for each sub-scale in NEI VFQ-25, 95%CI were shown with the lighter red ribbon
 175 around the smooth curves.

176 **3.3 Influence factors of visual loss in T2DM patients**

177 **3.3.1 Demographic variables in T2DM patients**

178 When demographic variables of T2DM patients, including age, gender and educational level were
 179 examined independently, we found that all these modifiers contributed to the overall effect of the
 180 hyperglycemic metabolic disorder (Table 3). In all sub-scales other than color vision, older age and
 181 lower educational level contributed to lower scores of NEI VFQ-25, therefore indicating higher risks of
 182 visual functional loss and heavier dependence on caregivers in vision-related tasks. Female patients
 183 exhibited poorer visual performance, however, we found that gender had no effect on the decline of
 184 visual function after matching female and male patients with age. Among all demographic features, the
 185 age of patients had the greatest impact on visual impairment, as the *F*-value for age, gender and
 186 education level were 6.592, 3.026, and 1.068, respectively. In the color vision sub-scale, on the contrary,
 187 none of all the demographic features were shown to leave either positive or negative effect.

188 **TABLE 3 Visual functions in T2DM patients stratified by demographic features**

| Subscales | Near Activities | Distance Activities | Social Functioning | General Vision | Peripheral Vision | Color Vision | Total |
|------------------|----------------------------|--------------------------------|-------------------------------|---------------------------|------------------------------|-------------------------|--------------|
| Age | | | | | | | |
| 20-29 | 95.83 | 91.67 | 93.75 | 70.00 | 87.50 | 100.00± | 93.75±8 |
| (n=2) | ±5.89 | ±11.79 | ±8.84 | ±14.14 | ±17.68 | 0.00 | .84 |
| 30-39 | 92.95 | 93.27 | 95.67 | 72.31 | 92.31 | 96.00 | 93.93 |
| (n=26) | ±15.58 | ±12.25 | ±11.15 | ±15.05 | ±13.73 | ±11.81 | ±11.44 |

| | | | | | | | |
|--------------------------|-----------|-----------|-----------|---------|---------|--------|---------------|
| 40-49 | 90.85 | 93.44 | 93.88 | 68.09 | 95.21 | 93.18 | 93.38 |
| (n=47) | ±16.14 | ±15.14 | ±11.15 | ±16.50 | ±14.41 | ±20.43 | ±15.04 |
| 50-59 | 84.46 | 90.09 | 95.16 | 64.86 | 92.79 | 95.27 | 91.55 |
| (n=111) | ±18.00 | ±15.06 | ±13.18 | ±14.82 | ±16.30 | ±12.84 | ±12.83 |
| 60-69 | 81.97 | 88.92 | 94.84 | 63.89 | 92.48 | 95.60 | 90.74 |
| (n=144) | ±22.39 | ±17.94 | ±12.35 | ±15.20 | ±19.01 | ±14.37 | ±14.51 |
| 70-79 | 71.53 | 75.68 | 87.09 | 59.34 | 81.25 | 91.67 | 81.35 |
| (n=61) | ±26.05 | ±24.62 | ±18.95 | ±14.59 | ±24.63 | ±18.79 | ±18.69 |
| 80-89 | 67.86 | 70.23 | 71.43 | 57.14 | 78.57 | 95.00 | 73.78 |
| (n=7) | ±28.23 | ±43.53 | ±31.22 | ±13.80 | ±39.33 | ±11.18 | ±33.86 |
| 90-99 | | | | | | | |
| (n=1) | 12.5 | - | - | 40 | - | - | 12.5 |
| p-value | <0.001*** | <0.001*** | <0.001*** | 0.004** | 0.001** | 0.699 | <0.001* ** |
| Gender | | | | | | | |
| Male | 86.25 | 91.01 | 94.65 | 67.02 | 93.05 | 95.30 | 91.98 |
| (n=188) | ±18.11 | ±16.49 | ±12.49 | ±15.54 | ±16.75 | ±14.63 | ±13.46 |
| Female | 79.11 | 84.74 | 92.00 | 61.98 | 88.93 | 94.14 | 87.40 |
| (n=212) | ±24.34 | ±21.01 | ±17.14 | ±14.89 | ±21.31 | ±15.84 | ±17.89 |
| p-value | 0.001** | 0.001** | 0.077 | 0.001** | 0.032* | 0.451 | 0.004** |
| Educational level | | | | | | | |

| | | | | | | | |
|----------------|-----------|-----------|--------|---------|-----------|--------|---------------|
| Illiteracy | 54.17 | 66.67 | 83.75 | 50.00 | 62.50 | 86.11 | 70.13 |
| (n=10) | ±32.45 | ±26.06 | ±16.72 | ±23.57 | ±29.46 | ±18.16 | ±19.57 |
| Primary | | | | | | | |
| School | 70.09 | 78.89 | 87.5 | 60.67 | 84.17 | 90.18 | 82.27 |
| (n=30) | ±28.76 | ±24.34 | ±24.34 | ±16.17 | ±24.99 | ±24.85 | ±22.47 |
| Secondary | | | | | | | |
| School | 79.07 | 86.84 | 93.47 | 62.25 | 92.82 | 94.54 | 88.58 |
| (n=87) | ±23.47 | ±18.82 | ±12.57 | ±16.08 | ±16.13 | ±13.44 | ±16.69 |
| High | | | | | | | |
| School | 82.39 | 88.19 | 92.89 | 64.12 | 90.67 | 95.05 | 89.85 |
| (n=106) | ±21.48 | ±19.66 | ±15.98 | ±14.44 | ±20.19 | ±14.15 | ±15.91 |
| Undergra | | | | | | | |
| duate | 87.85 | 90.39 | 94.63 | 66.62 | 92.63 | 95.75 | 92.13 |
| (n=152) | ±16.65 | ±17.00 | ±13.77 | ±14.03 | ±17.56 | ±14.84 | ±13.38 |
| Graduate | | | | | | | |
| or above | 90.28 | 93.75 | 98.96 | 73.33 | 95.83 | 95.83 | 94.93 |
| (n=12) | ±12.73 | ±8.79 | ±3.61 | ±15.57 | ±9.73 | ±9.73 | ±7.00 |
| p-value | <0.001*** | <0.001*** | 0.045* | 0.001** | <0.001*** | 0.293 | <0.001* ** |

189 n=number

190 $p < 0.05$ was marked with* $p < 0.01$ was marked with** $p < 0.001$ was marked with***

191 3.3.2 *Diabetic parameters in T2DM patients*

192 Moreover, we evaluated the duration of T2DM, FPG and HbA1c level, which were key factors
193 determining the degree of T2DM to explore their impact on the vision function related to quality of life.
194 As shown in Figure 2A, the duration of T2DM negatively correlated with scores of each sub-scale and
195 total score of NEI VFQ-25 except for color vision. The scores of patients with a course of more than 20
196 years decreased significantly, suggesting that 20 year is a significant cut-off point. With the extension
197 of the course of diabetes, the scores of near activities decreased gradually and might serve as a more
198 sensitive parameter in evaluating visual loss.


199 Elevated fasting blood glucose affects near activities, distance activities, social functioning, color
200 vision and total score (Figure 2B). In peripheral vision sub-scale however, significant functional loss
201 wasn't observed until patients' FPG reached 10mmol/l, whereas scores for general vision didn't differ
202 much when patients' FPG exceeded 15mmol/l, as relative lower FPG level and better control of
203 T2DM's hyperglycemic effect might elevate patients' expectation in vision-related quality of life and
204 lower their general satisfaction regarding visual functions.

205 As an indicator of blood glucose control in recent 3 months, HbA1c will also affect visual function.
206 With the increase of HbA1c, all sub-scales and the scores of NEI VFQ-25 decreased gradually. Total as
207 well as mean score for near activities and peripheral vision decreased with the increase of HbA1c,
208 while scores for social functioning went through a cut-off point as the scope of decrease changed when
209 HbA1c reached around 7.5%. Additional multivariate analysis indicated that diabetic duration, FPG

210 and HbA1c level had influence on scores of NEI VFQ-25. However, duration of T2DM produced the
 211 highest proportion of overall visual impairments among the three, with a *F*-value of 1.842 compared
 212 with FPG (*F*=1.344, multivariate analysis) and HbA1c (*F*=1.069).

213 *3.3.3 Ocular parameters in T2DM patients*

214 Moreover, the correlation between the average BCVA of both eyes, the presence of retinopathy and
 215 visual functional loss were examined using both non-linear regression model and independent t-test. As
 216 shown in Figure 2D, scores for each sub-scale and total score were found to decrease as BCVA
 217 worsened, with potential cut-off point identified at an average BCVA of 0.4. Color vision, however,
 218 weren't shown to display either positive or negative correlation with average BCVA of both eyes. The
 219 presence of diabetic retinopathy (DR), which was the main symbol for micro-vessel degeneration
 220 caused by chronic hyperglycemic condition, did present statistically significant results. DR sufferers,
 221 however, exhibited poorer performance in all sub-scales and total scores of NEI VFQ-25, with a
 222 *p*-value of 0.013 in color vision and *p*<0.001 in all other sub-scales, respectively.



223 **FIGURE 2 Correlation between visual functions and diabetic duration (a), FPG (b) , HbA1c (c)**

224 **and average vision (d)** Smooth curves along with 95%CI were demonstrated above indicating the

225 progression of functional loss in each vision-related sub-scales as duration of T2DM lengthened, FPG

226 and HbA1c elevated and average vision deteriorated.

227 In general, older age, lower educational, long duration of T2DM, elevated FPG and HbA1c level were

228 identified risk factors involved in visual impairment, whereas age and duration of T2DM were the two

229 most important factors. Poorer BCVA and the presence of diabetic retinopathy, on the other hand, were

230 not only independent risk factors, but also essential mediators in the long-term effect of longer duration

231 of T2DM, higher FPG and HbA1c level.

232 *3.3.4 Mediation effect analysis of different modifiers*

233 Through analysis of relationship between diabetic duration, BCVA and scores for sub-scales as well as

234 total scores of NEI VFQ-25, we found that longer duration negatively impacted on T2DM patients'

235 multiple visual functions through deterioration of average BCVA, and mean proportion of the

236 mediation effect in different sub-scales ranged from 19.20% to 42.70%. Similar mediation effect was

237 found in FPG, HbA1c and NEI VFQ-25. The proportion of mediation effect was shown in Table 4,

238 which pointed out that the mediation effect of average BCVA was more statistically significant than the

239 presence of diabetic retinopathy Furthermore, color vision and social functioning sub-scale were the

240 least likely to be influenced by the mediation effect of the two ophthalmologic parameters. General

241 vision on the contrary, was demonstrated to have BCVA and the presence of retinopathy share the

242 largest proportion of contribution, as subjective thoughts towards one's general vision might be the
 243 most sensitive to subtle changes in eyesight and was the earliest sub-scale to be influenced by the
 244 diagnosis of diabetic retinopathy.

245 **TABLE 4 Mediation effect of BCVA and diabetic retinopathy**

| Mediation Effect (%) | Near Activities | Distance Activities | Social Functioning | General Vision | Peripheral Vision | Color Vision | Total Score |
|-------------------------------|------------------------|----------------------------|---------------------------|-----------------------|--------------------------|---------------------|--------------------|
| Diabetic duration-BCVA | 19.93*** | 28.06*** | 19.20* | 36.40** | 42.70** | 20.89 | 29.22** * |
| FPG-BCVA | 47.30*** | 46.60*** | 51.70*** | 58.20*** | 54.50*** | 25.40** | 62.00* |
| HbA1c-BCVA | 29.60* | 55.81** | 5.56 | 18.20* | 27.40* | 1.97 | 27.89 |
| Diabetic duration-Retinopathy | 77.6 | 49.01 | 63.42 | 33.00 | 61.57 | 52.91 | 73.77 |
| FPG-Retinopathy | 33.40 | 21.70 | 18.90 | 29.70 | 24.10 | 8.97 | 24.80 |
| HbA1c-Retinopathy | 19.20 | 11.90 | 13.69 | 60.20 | 5.97 | 5.79 | 15.50 |

246 FPG=Fasting plasma glucose, HbA1c=glycosylated hemoglobin A1c, BCVA=best corrected visual

247 acuity

248 $p < 0.05$ was marked with* $p < 0.01$ was marked with** $p < 0.001$ was marked with***

249 **Discussion**

250 Our study presented a cross sectional survey that examined visual functional loss in T2DM patients,
251 identified risk factors as well as protective factors that modified patients' performance. We found that
252 visual functional loss was more common and significant in T2DM patients compared with non-T2DM
253 participants, with the scope of visual impairment in T2DM patients shown to be larger and the
254 progression comparably faster. Old age, low educational, long duration of T2DM, elevated blood
255 glucose level (FPG and HbA1c), poor BCVA and the presence of diabetic retinopathy negatively
256 correlates with visual performance and vision-related quality of life among T2DM patients. 60 years of
257 age , 20 years of diabetic duration, 10 mmol/L of FPG, and 7.5% of HbA1c might be the cut-off point
258 of vision decline. Average vision and the presence of retinopathy, on the other hand, were either
259 independent modifiers and essential mediators that mediated the effect of diabetic duration, FPG and
260 HbA1c level.

261 In our study, the degree of visual loss was found to be of a higher extent in T2DM patients than
262 non-T2DM participants, while the visual functions of T2DM patients decreased more significantly as
263 age increased. As reported in prior studies, older patients were more susceptible to stressors
264 contributing to diabetic vascular changes, including oxidative stress, metabolic products and other toxic
265 transmitters^[3,8,9]. Patients of older age also suffer from more complicated comorbidities and geriatric
266 syndromes, which brought challenges to proper glycemic control and thus were likely to go through

267 rapid impairments of functional loss in vision-related activities^[10].

268 Applying a non-linear regression model, we identified that both T2DM patients and non-T2DM

269 participants exhibited a single-peak shaped pattern of functional loss as age grew. Younger patients,

270 however, weren't shown to perform better than patients in their 40s or 50s. For T2DM patients, on the

271 one hand, this single peak-shaped correlation might be explained with the fact that those who

272 developed T2DM at younger age probably suffer from more severe eye disease and yet were more

273 sensitive to functional loss in vision-related activities. As reported by Song et al^[11], the prevalence and

274 degree of visual loss in T2DM increased substantially after patients reached their middle age, while

275 studies featuring younger population indicated that diabetic retinopathy in prepubescent children,

276 teenagers and young adults might be of higher severity and faster progression since insulin

277 requirements in adolescence were relatively high, and teenage hormonal axis were immature and less

278 sensitive to drugs^[12]. On the other hand, younger non-T2DM patients might generally go through more

279 frequent yet complicated visual tasks and required higher vision related quality of life compared with

280 senior participants, which helps to explain why young participants scored lower than middle-aged

281 participants. In the general vision sub-scale however, there was no significant differences in scores

282 between two groups, which could possibly be explained by the fact that non-T2DM participants were

283 more involved in vision-related tasks and thus set a higher standard for maintaining satisfactory visual

284 performance. We concluded that both adolescent and senior T2DM patients should be paid with special

285 attention as their physical condition featured more complicated comorbidities, higher hormone

286 requirements and lower compliance, which therefore called for strict glycemic control and systematic

287 disease administration.

288 Paralleled to prior studies, both old age and low educational level were thought to be risk factors
289 predicting poorer visual functions and vision-related quality of life^[2,13,14]. Effect of other demographic
290 features such as gender varied in different cohorts. In 2013, a study in Japan found that female
291 participants had a higher prevalence of diabetic retinopathy at baseline and were more likely to develop
292 severe retinopathy with the development of diabetes^[15]. However, more studies suggested that the male
293 sex was an independent risk factor for the high prevalence and progression, emphasizing the protective
294 effect of estrogen and identifying testosterone and androgen as detrimental to diabetic micro-vascular
295 complications^[16,17].

296 For parameters determining severity of T2DM, duration of disease, elevated FPG and HbA1c level
297 were generally found to negatively impacted on visual performances. Nonetheless, different edge
298 points were confirmed in different studies. Olivarius et al used a FPG 10 and 17 mmol/L along with a
299 HbA1c 9% and 11% respectively, whereas Foo et al ascertained a transformation zone of HbA1c
300 7%-8%^[14,18]. The variation in the selection of the cut-off point for HbA1c could be explained by the
301 different study procedures in two cohorts. Olivarius et al on the one hand, used average vision as the
302 major parameter assessing visual loss, while on the other hand, moderate diabetic retinopathy was seen
303 as the observational outcome in the latter report^[14]. Moderate diabetic retinopathy, diagnosed by
304 proliferation of micro-vessels through fundus photography, led to a lower cut-off point of HbA1c, with
305 subjective visual loss being less sensitive and were unable to give an early warning of visual loss until
306 HbA1c reached 9%^[14,18]. Therefore, we suggested that fundus degeneration symbolized by vascular
307 changes, which was sensitive to hyperglycemic conditions, might accounted for the low scores in
308 relative sub-scales as diabetic duration lengthened and blood glucose level elevated. Moreover, 20

309 years' of diabetic duration were regarded as probable cut-off point in a Tunisian cohort conducted in
310 2014^[19], while Liu et al reported 15 years to be a meaningful stage symbolizing severe ocular
311 degeneration^[20]. Such differences were possibly due to the different definitions of visual loss, as
312 outcome indicators were subjective visual symptoms in some studies while others used rating scales or
313 ocular examinations as diagnostic tools. In our study, both subjective evaluation of visual loss and
314 objective tools determining BCVA were applied, with more detailed definition of different types of
315 visual functional defect and degree of decreased vision-related quality of life using the NEI VFQ-25
316 rating scale. Such combination of diagnostic tools defined relatively sensitive cut-off point of HbA1c
317 and FPG level, while the cut-off point of T2DM duration were not as sensitive as expected. This
318 emphasized the need for appropriate yet comprehensive combination of different diagnostic tools, and
319 also early intervention of T2DM as no golden standard of cut-off points were so far established.
320 Additionally, the insignificant effect of early elevation of FPG and HbA1c were possibly due to the
321 fluctuation of long term glycemic control, as related studies stated that the oscillation of blood glucose
322 boasted higher predictive value rather than parameters determining average blood glucose level^[21,22].

323 Ocular parameters, namely average BCVA and baseline retinopathy in our study, were considered as
324 essential modifiers of visual functions. Poorer vision and the existence of ocular vascular degeneration
325 limited the scale and acuity of optesthesia in T2DM patients thus disturbed their vision-related quality
326 of life in several ways including elevating intraocular pressure and damaging nerve fiber layers^[19,23].
327 However, some reports revealed the protective effect of myopia on the development of diabetic
328 retinopathy, which may indicate that patients suffered from myopia were less likely to develop diabetic
329 retinopathy, but such protective effect disappeared once diabetic retinopathy ensued.

330 The mediation effect of average BCVA and baseline diabetic retinopathy, accounted for different
331 proportions of functional loss in various NEI VFQ-25 sub-scales. General vision was the most sensitive
332 sub-scale influenced by poor eyesight, as participants mainly judge their autonomous performance in
333 vision-related daily tasks based on the average vision of both eyes. The different proportion of
334 mediation effect generated by average BCVA and baseline diabetic retinopathy helped to illustrate that
335 early degradation of eyesight or diagnosis of retinopathy were relatively asymptomatic, as they might
336 not be directly reflected by clear signs of vision-related disabilities in daily life. Furthermore, visual
337 symptoms other than decreased eyesight and ophthalmologic diagnosis besides diabetic retinopathy
338 were equally important and needed to be carefully taken into consideration.

339 Another interesting finding regarding visual loss was the patients' performance in color vision. As
340 mentioned previously, the decline in color vision, which was embodied by the ability to choose clothes
341 in NEI VFQ-25, was not associated with the development of T2DM. Moreover, little evidence of either
342 positive or negative correlations found between several modifiers and color vision scores. Such
343 insignificant results contradicted with prior studies reporting loss of color vision in T2DM patients and
344 associating risk factors with deteriorated color vision^[24,25]. Yet the contradictory findings might be due
345 to the fact that the setting of evaluating loss of color vision were different. Some cohorts came up with
346 the conclusion using specific rating scales such as D-15 color test or Cambridge color test while others
347 were based on integrated rating scales assessing general vision-related quality of life. Still other
348 methods such as machinery tests or patients' subjective feedback were included in some studies.
349 However, it was still worth noticing that most color vision loss were sub-clinical and might not be

350 detected using certain techniques. Additionally, the subtle loss of color vision could be covered by
351 physiological decline in color vision caused by aging, therefore called for early evaluation of color
352 vision and visual complications accompanying T2DM.

353 Above all, the confirmation of effect driven by different modifiers and the pattern of functional loss in
354 T2DM patients collaboratively promoted the urgent need of early diagnosis, in-time intervention, strict
355 administration and systematic follow-up of all T2DM patients. T2DM patients with multiple risk
356 factors should be paid with more attention and patient-centered therapeutic strategies should be
357 administered. Efficient screening and timely treatment using portable eye examination units guaranteed
358 decreased rate of visual impairments by 86% in T2DM patients, as reported by a Finnish cohort carried
359 out in more than 14 thousand patients, emphasizing valuable prospective value of taking early action
360 by healthcare professionals^[26]. Moreover, the absence of intensive blood glucose administration may
361 exacerbate the progression of T2DM. Hu et al reported that positive correlation between annual increase
362 of FPG and narrowing of retinal arterioles^[27].

363 There are several limitations to our study. First, it is a cross-sectional study via an online questionnaire,
364 through which a strict causal relationship or quantified correlations between each modifier and
365 functional loss cannot be concluded. Second, quality control was based on the time that each
366 participant spent completing the questionnaire only, which might not be sufficient to prevent certain
367 recall bias. Third, we didn't specifically match every T2DM patient with a non-T2DM participants
368 whose basic information were similar, instead, rough classification of all participants was done
369 according to a 10-year age range. Therefore, longitudinal data from larger samples was needed to verify

370 the above conclusions, and further research might investigate the mechanism and progression of certain
371 ophthalmologic complications and find out certain parameters with predictive values.

372 To sum up, our study suggested that attention should be paid to the visual function of patients with
373 T2DM , specifically in patients with old age, low educational level, long course of disease, irregular
374 self-monitoring of blood glucose, limited eyesight, and those who had already been diagnosed with
375 diabetic retinopathy. Certain cut-off points were identified, whereas ophthalmologic parameters served
376 as essential mediators of the overall long-term hyperglycemic effect. We emphasized the importance of
377 early diagnosis, in-time intervention and careful administration of T2DM and use more comprehensive
378 parameters to evaluate the severity of visual function in T2DM patients.

379 **References**

- 380 The Lancet(2020) Diabetes Endocrinology Under the lens: diabetic retinopathy. Lancet Diabetes
381 Endocrinol. 8(11):869. doi: 10.1016/S2213-8587(20)30347-8. Epub 2020 Oct 7. PMID: 33038294.
- 382 Ogurtsova K, da Rocha Fernandes JD, Huang Y(2017) IDF Diabetes Atlas: Global estimates for the
383 prevalence of diabetes for 2015 and 2040. Diabetes Res Clin Pract. 128:40-50.
384 doi:10.1016/j.diabres.2017.03.024
- 385 Heng LZ, Comyn O, Peto T(2013) Diabetic retinopathy: pathogenesis, clinical grading, management
386 and future developments. Diabet Med. 30(6):640-650. doi:10.1111/dme.12089
- 387 Romero-Aroca P, Baget-Bernaldiz M, Pareja-Rios A, Lopez-Galvez M, Navarro-Gil R, Verges R(2016)
388 Diabetic Macular Edema Pathophysiology: Vasogenic versus Inflammatory. J Diabetes Res.
389 2016;2016:2156273. doi:10.1155/2016/2156273

390 Morrish NJ, Wang SL, Stevens LK, Fuller JH, Keen H(2001) Mortality and causes of death in the
391 WHO Multinational Study of Vascular Disease in Diabetes. *Diabetologia*. 2001;44 Suppl 2:S14-S21.
392 doi:10.1007/pl00002934

393 Cusick, M., SanGiovanni, J. P., Chew, E. Y., Csaky, K. G., Hall-Shimel, K., Reed, G. F., Caruso, R. C.,
394 & Ferris, F. L., 3rd (2005) Central visual function and the NEI-VFQ-25 near and distance activities
395 subscale scores in people with type 1 and 2 diabetes. *American journal of ophthalmology*, 139(6), 1042
396 - 1050. <https://doi.org/10.1016/j.ajo.2005.01.008>

397 Mangione, C. M., Lee, P. P., Gutierrez, P. R., Spritzer, K., Berry, S., Hays, R. D., & National Eye
398 Institute Visual Function Questionnaire Field Test Investigators (2001) Development of the 25-item
399 National Eye Institute Visual Function Questionnaire. *Archives of ophthalmology (Chicago, Ill. :*
400 1960), 119(7), 1050 - 1058. <https://doi.org/10.1001/archophth.119.7.1050>

401 Hariprasad, S. M., Mieler, W. F., Grassi, M., Green, J. L., Jager, R. D., & Miller, L. (2008)
402 Vision-related quality of life in patients with diabetic macular oedema. *The British journal of*
403 *ophthalmology*, 92(1), 89 - 92. <https://doi.org/10.1136/bjo.2007.122416>

404 Trento, M., Passera, P., Trevisan, M., Schellino, F., Sitia, E., Albani, S., Montanaro, M., Bandello, F.,
405 Scoccianti, L., Charrier, L., Cavallo, F., & Porta, M. (2013) Quality of life, impaired vision and social
406 role in people with diabetes: a multicenter observational study. *Acta diabetologica*, 50(6), 873 - 877.
407 <https://doi.org/10.1007/s00592-013-0470-1>

408 Araki, A., & Ito, H. (2009) Diabetes mellitus and geriatric syndromes. *Geriatrics & gerontology*
409 *international*, 9(2), 105 - 114. <https://doi.org/10.1111/j.1447-0594.2008.00495.x>

410 Song, P., Yu, J., Chan, K. Y., Theodoratou, E., & Rudan, I. (2018) Prevalence, risk factors and burden
411 of diabetic retinopathy in China: a systematic review and meta-analysis. *Journal of global health*, 8(1),

412 010803. <https://doi.org/10.7189/jogh.08.010803>

413 Ben Mehidi, A., Massin, P., Guyot-Argenton, C., Erginay, A., Guillausseau, P. J., & Gaudric, A. (2003)

414 La rétinopathie diabétique du sujet jeune: l'enfant et l'adolescent [Diabetic retinopathy in children and

415 adolescents]. *Diabetes & metabolism*, 29(3), 300 – 306.

416 Danet-Lamasou, M., Pérès, K., Matharan, F., Berr, C., Carrière, I., Tzourio, C., Delcourt, C., &

417 Bourdel-Marchasson, I. (2018) Near Visual Impairment Incidence in Relation to Diabetes in Older

418 People: The Three-Cities Study. *Journal of the American Geriatrics Society*, 66(4), 699 – 705.

419 de Fine Olivarius, N., Siersma, V., Almind, G. J., & Nielsen, N. V. (2011) Prevalence and progression

420 of visual impairment in patients newly diagnosed with clinical type 2 diabetes: a 6-year follow up

421 study. *BMC public health*, 11, 80. <https://doi.org/10.1186/1471-2458-11-80>

422 Kajiwara, A., Miyagawa, H., Saruwatari, J., Kita, A., Sakata, M., Kawata, Y., Oniki, K., Yoshida, A.,

423 Jinnouchi, H., & Nakagawa, K. (2014) Gender differences in the incidence and progression of diabetic

424 retinopathy among Japanese patients with type 2 diabetes mellitus: a clinic-based retrospective

425 longitudinal study. *Diabetes research and clinical practice*, 103(3), e7 – e10.

426 <https://doi.org/10.1016/j.diabres.2013.12.043>

427 Ozawa, G. Y., Bearse, M. A., Jr, & Adams, A. J. (2015) Male-female differences in diabetic

428 retinopathy?. *Current eye research*, 40(2), 234 – 246. <https://doi.org/10.3109/02713683.2014.958500>

429 Maric-Bilkan C. (2017) Sex differences in micro- and macro-vascular complications of diabetes

430 mellitus. *Clinical science (London, England : 1979)*, 131(9), 833 – 846.

431 <https://doi.org/10.1042/CS20160998>

432 Foo, V., Quah, J., Cheung, G., Tan, N. C., Ma Zar, K. L., Chan, C. M., Lamoureux, E., Tien Yin, W.,

433 Tan, G., & Sabanayagam, C. (2017) HbA1c, systolic blood pressure variability and diabetic retinopathy

434 in Asian type 2 diabetics. *Journal of diabetes*, 9(2), 200 – 207. <https://doi.org/10.1111/1753-0407.12403>

435 Kahloun, R., Jelliti, B., Zaouali, S., Attia, S., Ben Yahia, S., Resnikoff, S., & Khairallah, M. (2014)

436 Prevalence and causes of visual impairment in diabetic patients in Tunisia, North Africa. *Eye (London,*

437 *England)*, 28(8), 986 – 991. <https://doi.org/10.1038/eye.2014.131>

438 Liu, Y., Duan, C., Fang, D., Liu, Y., Xu, H., Zheng, Y., Xuan, Y., Wang, L., Ye, L., Su, R., & An, M.

439 (2019) Protective factors for diabetic retinopathy in Type 2 diabetes mellitus patients: Long duration of

440 no less than 10 years. *Journal of diabetes and its complications*, 33(10), 107383.

441 <https://doi.org/10.1016/j.jdiacomp.2019.05.014>

442 Škrha, J., Šoupal, J., Škrha, J., Jr, & Prázný, M. (2016) Glucose variability, HbA1c and microvascular

443 complications. *Reviews in endocrine & metabolic disorders*, 17(1), 103 – 110.

444 <https://doi.org/10.1007/s11154-016-9347-2>

445 Hsieh, Y. T., & Hsieh, M. C. (2020) Fasting plasma glucose variability is an independent risk factor for

446 diabetic retinopathy and diabetic macular oedema in type 2 diabetes: An 8-year prospective cohort

447 study. *Clinical & experimental ophthalmology*, 48(4), 470 – 476. <https://doi.org/10.1111/ceo.13728>

448 Lim, H. B., Shin, Y. I., Lee, M. W., Lee, J. U., Lee, W. H., & Kim, J. Y. (2020) Association of Myopia

449 with Peripapillary Retinal Nerve Fiber Layer Thickness in Diabetic Patients Without Diabetic

450 Retinopathy. *Investigative ophthalmology & visual science*, 61(10), 30.

451 <https://doi.org/10.1167/iovs.61.10.30>

452 Feitosa-Santana, C., Paramei, G. V., Nishi, M., Gualtieri, M., Costa, M. F., & Ventura, D. F. (2010)

453 Color vision impairment in type 2 diabetes assessed by the D-15d test and the Cambridge Colour

454 Test. *Ophthalmic & physiological optics : the journal of the British College of Ophthalmic Opticians*

455 (Optometrists), 30(5), 717 – 723. <https://doi.org/10.1111/j.1475-1313.2010.00776.x>

456 Wolff, B. E., Bearse, M. A., Jr, Schneck, M. E., Dhamdhere, K., Harrison, W. W., Barez, S., & Adams,
457 A. J. (2015) Color vision and neuroretinal function in diabetes. *Documenta ophthalmologica. Advances*
458 *in ophthalmology*, 130(2), 131 - 139. <https://doi.org/10.1007/s10633-014-9476-4>

459 Hautala, N., Aikkila, R., Korpelainen, J., Keskitalo, A., Kurikka, A., Falck, A., Bloigu, R., & Alanko, H.
460 (2014) Marked reductions in visual impairment due to diabetic retinopathy achieved by efficient
461 screening and timely treatment. *Acta ophthalmologica*, 92(6), 582 - 587.
462 <https://doi.org/10.1111/aos.12278>

463 Hu, Y., Niu, Y., Wang, D., Wang, Y., Holden, B. A., & He, M. (2015) The association of longitudinal
464 trend of fasting plasma glucose with retinal microvasculature in people without established
465 diabetes. *Investigative ophthalmology & visual science*, 56(2), 842 - 848.
466 <https://doi.org/10.1167/iovs.14-15943>

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- [Supplementaryfiles.pdf](#)